secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0001831283-23-000145
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 1.02
LLM model:  deepseek-v4-flash:cloud@v2

LianBio sells NBTXR3 rights in Asia to Janssen for $25M upfront plus potential $5M milestone
--------------------------------------------------------------------------------

- Asset Purchase Agreement with Janssen (Johnson & Johnson) executed Dec 22, 2023.
- LianBio receives $25 million one-time payment at closing.
- Eligible for $5 million milestone if annual net sales in PRC exceed $20 million.
- Transition activities to be completed within six months post-closing.
- Concurrent Novation Agreement with Nanobiotix consenting to the deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/0001831283-23-000145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/lian-20231222.htm
  HTML page:      https://secwatch.observer/filing/0001831283-23-000145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer